LIVE/VIRTUAL ACTIVITIES

Bio Ascend – Designing CME Solutions For a Virtual World, Our Live and Virtual CME Activities Are Designed to Keep HCPs Educated.

Bio Ascend helps healthcare providers (HCPs) like you stay educated by providing the CME resources you need for continuing education. Our vast selection of activities is devoted entirely to solid tumor and hematologic malignancies – with engaging options in both in-person and virtual environments. Activities feature leading experts discussing the latest data and how to apply it to clinical practice, providing you with critical insight and direction on how to incorporate therapeutic advancements into your practice.

Satellite Symposia:
New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

June 15, 2021 – Virtual
Time: 7:00 PM – 8:45 PM EDT

There are no fees to register for this symposium
This live-streamed independent satellite symposium will take place following the #ASCO21 Meeting and will be presented on an interactive web platform by 3 renowned experts actively engaged in the care of patients with multiple myeloma. Be sure to check back in July to view the CME-certified Expert Insights recording with two of the symposium faculty who will provide a summarization of the symposium’s take-home messages most relevant to practice and clinical decision making.
Agenda
7:00PM
Welcome, Introductions, and Pre-session Survey
7:10PM
Evolving Profile of a Patient with Relapsed/Refractory MM
 Therapies recently moved to the frontline setting and what it means for rrMM care
7:25PM

Clinical experience with CAR T-cell therapy for lymphoma and myeloma

  • CD19-targeting
  • BCMA-targeting
7:55PM

How to manage novel AE profiles

  • Cytokine release syndrome
  • Neurotoxicity
8:20PM

Practical aspects of CAR T-cell therapy

  • Choosing the right patient for CAR T-cell therapy
  • Optimizing the referral process and multdisciplinary care
8:40PM
Panel Discussion and Audience Q&A
8:50PM
Recap of Key Points and Post-Session Survey
9:00PM
Program Adjourns

Symposium Chair

Noopur Raje, MD
Massachusetts General Hospital

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
International Myeloma Foundation

Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center

Satellite Symposia:
New Targets, New Agents, New Combinations: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma

June 15, 2021 – Virtual
Time: 7:00 PM – 8:45 PM EDT

There are no fees to register for this symposium

This live-streamed independent satellite symposium will take place following the #ASCO21 Meeting and will be presented on an interactive web platform by 3 renowned experts actively engaged in the care of patients with multiple myeloma.

Be sure to check back in July to view the CME-certified Expert Insights recording with two of the symposium faculty who will provide a summarization of the symposium’s take-home messages most relevant to practice and clinical decision making.

Symposium Chair

Noopur Raje, MD Massachusetts General Hospital

Faculty

Joseph Mikhael, MD, MEd, FRCPC, FACP
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
International Myeloma Foundation

Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center

Agenda
7:00PM
Welcome, Introductions, and Pre-session Survey
7:10PM
Evolving Profile of a Patient with Relapsed/Refractory MM
 Therapies recently moved to the frontline setting and what it means for rrMM care
7:25PM

Clinical experience with CAR T-cell therapy for lymphoma and myeloma

  • CD19-targeting
  • BCMA-targeting
7:55PM

How to manage novel AE profiles

  • Cytokine release syndrome
  • Neurotoxicity
8:20PM

Practical aspects of CAR T-cell therapy

  • Choosing the right patient for CAR T-cell therapy
  • Optimizing the referral process and multdisciplinary care
8:40PM
Panel Discussion and Audience Q&A
8:50PM
Recap of Key Points and Post-Session Survey
9:00PM
Program Adjourns